Abbott Laboratories (ABT)vsElutia Inc. (ELUT)
ABT
Abbott Laboratories
$113.74
-1.65%
HEALTHCARE · Cap: $184.98B
ELUT
Elutia Inc.
$0.75
-1.15%
HEALTHCARE · Cap: $36.36M
Smart Verdict
WallStSmart Research — data-driven comparison
Abbott Laboratories generates 397304% more annual revenue ($48.23B vs $12.14M). ELUT leads profitability with a 426.9% profit margin vs 9.8%. ABT earns a higher WallStSmart Score of 52/100 (C-).
ABT
Buy52
out of 100
Grade: C-
ELUT
Avoid35
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-38.8%
Fair Value
$76.51
Current Price
$113.74
$37.23 premium
Margin of Safety
-0.0%
Fair Value
$0.90
Current Price
$0.75
$0.15 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Generating 2.1B in free cash flow
Every $100 of equity generates 221 in profit
Keeps 427 of every $100 in revenue as profit
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Earnings declined 43.7%
0.0% earnings growth
Smaller company, higher risk/reward
Revenue declined 11.6%
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ABT
The strongest argument for ABT centers on Market Cap, Free Cash Flow. Revenue growth of 14.5% demonstrates continued momentum.
Bull Case : ELUT
The strongest argument for ELUT centers on Return on Equity, Profit Margin, Price/Book. Profitability is solid with margins at 426.9% and operating margin at -243.1%.
Bear Case : ABT
The primary concerns for ABT are PEG Ratio, P/E Ratio, EPS Growth.
Bear Case : ELUT
The primary concerns for ELUT are EPS Growth, Market Cap, Revenue Growth.
Key Dynamics to Monitor
ABT profiles as a value stock while ELUT is a declining play — different risk/reward profiles.
ELUT carries more volatility with a beta of 0.92 — expect wider price swings.
ABT is growing revenue faster at 14.5% — sustainability is the question.
ABT generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
ABT scores higher overall (52/100 vs 35/100) and 14.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abbott Laboratories
HEALTHCARE · MEDICAL DEVICES · USA
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.
Visit Website →Elutia Inc.
HEALTHCARE · MEDICAL DEVICES · USA
Elutia Inc., a commercial-stage company, engages in developing and commercializing drug-eluting biomatrix technology to enhance surgical outcomes. The company is headquartered in Silver Spring, Maryland.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?